441 related articles for article (PubMed ID: 19797108)
1. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
2. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer.
Chang EY; Dorsey PB; Frankhouse J; Lee RG; Walts D; Johnson W; Anadiotis G; Johnson N
Arch Surg; 2009 Jun; 144(6):511-5. PubMed ID: 19528382
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
4. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
5. Low microsatellite instability is associated with poor prognosis in stage C colon cancer.
Kohonen-Corish MR; Daniel JJ; Chan C; Lin BP; Kwun SY; Dent OF; Dhillon VS; Trent RJ; Chapuis PH; Bokey EL
J Clin Oncol; 2005 Apr; 23(10):2318-24. PubMed ID: 15800322
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
7. Young age influences treatment but not outcome of colon cancer.
Quah HM; Joseph R; Schrag D; Shia J; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Ann Surg Oncol; 2007 Oct; 14(10):2759-65. PubMed ID: 17593332
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
9. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
Kim GP; Colangelo LH; Wieand HS; Paik S; Kirsch IR; Wolmark N; Allegra CJ;
J Clin Oncol; 2007 Mar; 25(7):767-72. PubMed ID: 17228023
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.
Meng WJ; Sun XF; Tian C; Wang L; Yu YY; Zhou B; Gu J; Xia QJ; Li Y; Wang R; Zheng XL; Zhou ZG
Oncology; 2007; 72(1-2):82-8. PubMed ID: 18004081
[TBL] [Abstract][Full Text] [Related]
12. [Colon cancer: what is new in 2004?].
André T; Louvet C; de Gramont A
Bull Cancer; 2004 Jan; 91(1):75-80. PubMed ID: 14975808
[TBL] [Abstract][Full Text] [Related]
13. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population.
Deschoolmeester V; Van Damme N; Baay M; Claes K; Van Marck E; Baert FJ; Wuyts W; Cabooter M; Weyler J; Vermeulen P; Lardon F; Vermorken JB; Peeters M
Eur J Cancer; 2008 Oct; 44(15):2288-95. PubMed ID: 18707864
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant therapy in colon cancer].
Reinacher-Schick A; Arnold D; Trarbach T; Ridwelski K; Bruch HP; Kirchner T; Kubicka S; Schmoll HJ
Onkologie; 2010; 33 Suppl 4():2-7. PubMed ID: 20431306
[TBL] [Abstract][Full Text] [Related]
19. Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer.
Ogata Y; Murakami H; Sasatomi T; Ishibashi N; Mori S; Ushijima M; Akagi Y; Shirouzu K
J Surg Oncol; 2009 Jan; 99(1):65-70. PubMed ID: 18942720
[TBL] [Abstract][Full Text] [Related]
20. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
